UNITED ~~STATES~~STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549

~~SECURITIES~~Form ~~AND EXCHANGE COMMISSION~~6-K

~~WASHINGTON,~~REPORT ~~D.C.~~OF ~~20549~~FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

SECURITIES EXCHANGE ACT OF 1934

For the month of July 2025

Commission File Number: 001-37652

Biodexa Pharmaceuticals PLC(Translation of registrant's name into English)

~~(Translation~~1 ofCaspian ~~registrant’s~~Point, ~~name~~Caspian ~~into~~Way, ~~English~~Cardiff, CF10 4DQ, United Kingdom(Address of principal executive office)

1Indicate ~~Caspian~~by ~~Point,~~check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.Form 20-F [ X ] Form 40-F [ ]

~~Caspian~~The ~~Way~~information included in this report on Form 6-K, including Exhibit 99.1, shall be deemed to be incorporated by reference into the registration statements on Form S-8 (File No. 333-214969) and Form F-3 (File No. 333-233901) of the Company (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

~~Cardiff,~~SUBMITTED ~~CF10 4DQ, United Kingdom~~HEREWITH:

(Address of principal executive offices)

Exhibit Number		Description

99.1		Press Release dated July 31, 2025

~~Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:~~SIGNATURES

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

The information included in this report on Form 6-K, including Exhibit 99.1, shall be deemed to be incorporated by reference into the registration statements on Form S-8 (File No. 333-209365) and Form F-3 (File No. 333-267932) of the Company (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

SUBMITTED HEREWITH

Attached to the Registrant’s Form 6-K filing for the month of July 2025 is:

Exhibit No.		Description
99.1		Press release dated July 15, 2025.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	~~Biodexa Pharmaceuticals PLC~~	Biodexa Pharmaceuticals PLC
Date: July 15, 2025	By:	/s/ Stephen Stamp
		(Registrant)
Date: July 31, 2025		/s/ Stephen Stamp
		Stephen Stamp
		Chief Executive Officer and Chief Financial Officer
		Chief Executive Officer, Chief Financial Officer

Filing Compare · Biodexa Pharmaceuticals Plc